{"id":"W4205969691","doi":"10.3324/haematol.2021.279012","title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"Cilag; Juno Therapeutics; Kite Pharma; Cancer Research UK; Genentech; Horizon Therapeutics; Pfizer; Moderna; Incyte; Pharmacyclics; Agios Pharmaceuticals; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Clovis Oncology; Teva Pharmaceutical Industries; AstraZeneca; Barts Charity; Exelixis; Karyopharm Therapeutics; Unum Therapeutics; Daiichi Sankyo Europe; Calithera Biosciences; Gilead Sciences; MorphoSys; Celgene; TG Therapeutics; Amgen; GlaxoSmithKline","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hazard ratio; Leukemia; Chemotherapy; Confidence interval; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00205035,0.001113649,0.002368458,0.0003942222,0.0003327086,0.001241856,0.0007849457,0.0009775138,0.001951661],"category_scores_gemma":[0.001000718,0.0004354446,0.002219978,0.0003603455,0.0006651889,0.0007002068,0.0004055011,0.002703861,0.0005163139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001455096,"about_ca_system_score_gemma":0.00121903,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001390415,"about_ca_topic_score_gemma":0.005128556,"domain_scores_codex":[0.9994442,0.0002887214,0.00002394567,0.00007645228,0.0000460327,0.0001206796],"domain_scores_gemma":[0.9992399,0.0001281316,0.0001683865,0.00005840026,0.00003847302,0.0003666448],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9085302,0.008273755,0.003339867,0.0005958766,0.001794412,0.00005687843,0.00009383036,0.001130123,0.005811094,0.0001532766,0.001792339,0.0684284],"study_design_scores_gemma":[0.8262088,0.1562365,0.01071308,0.0001044808,0.001114454,0.0001826465,0.00004065925,0.0009774776,0.001885469,0.0002042715,0.002301817,0.0000303634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827623,0.01082024,0.0006635325,0.0005294747,0.0004005169,0.001332863,0.0009146885,0.0001285134,0.002447935],"genre_scores_gemma":[0.990678,0.003310824,0.0007955994,0.0007234187,0.0002715805,0.0009546441,0.001565258,0.00002222164,0.001678455],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002368458,"threshold_uncertainty_score":0.01084346,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04504888166279691,"score_gpt":0.308024079257522,"score_spread":0.2629751975947251,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}